Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
- FDA grants Breakthrough Therapy Designation for trilaciclib based on myelopreservation data in small cell lung cancer patients - First clinical data on oral SERD G1T48 in breast cancer to be...
-
RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that the company will participate in two...
-
RESEARCH TRIANGLE PARK, N.C., July 31, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference...
-
RESEARCH TRIANGLE PARK, N.C., July 30, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced the appointment of Mark Avagliano as Chief...
-
- Detailed data from this trial will be presented at a medical meeting later this year - RESEARCH TRIANGLE PARK, N.C., June 18, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a...
-
RESEARCH TRIANGLE PARK, N.C., June 14, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that an analysis of patient-reported outcomes...
-
- Garry Nicholson to serve as new board chair -- Sir Andrew Witty, Fredric Eshelman, Pharm.D. and prior chair Seth Rudnick, M.D. re-elected - RESEARCH TRIANGLE PARK, N.C., June 13, 2019 (GLOBE...
-
RESEARCH TRIANGLE PARK, N.C., June 11, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca,...
-
RESEARCH TRIANGLE PARK, N.C., June 01, 2019 (GLOBE NEWSWIRE) -- - New patient-reported outcomes data shows trilaciclib improves chemotherapy experience for patients - G1 Therapeutics, Inc. (Nasdaq:...
-
RESEARCH TRIANGLE PARK, N.C., May 16, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that additional findings from a Phase 2...